Abstract
Studies showed that gamma-linolenic acid (GLA) and its derivatives have the potential to be anti-cancer molecules. In vitro, in vivo and limited clinical studies showed that GLA has selective tumoricidal action with little or no side effects. The mechanism of its action appears to be by inducing apoptosis of tumor cells by augmenting free radical generation only in the tumor cells but not normal cells. Intra-arterial injection of a lithium salt derivative of GLA demonstrated its ability to selectively occlude tumor-feeding vessels. Since GLA is an endogenous naturally occurring molecule and has no significant side effects, it calls for more studies to exploit its potential as a novel anti-cancer drug.
Keywords: eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), COX 1, intracellular calcium, Glioma
Current Pharmaceutical Biotechnology
Title: Tumoricidal and Anti-Angiogenic Actions of Gamma-Linolenic Acid and Its Derivatives
Volume: 7 Issue: 6
Author(s): Undurti N. Das
Affiliation:
Keywords: eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), COX 1, intracellular calcium, Glioma
Abstract: Studies showed that gamma-linolenic acid (GLA) and its derivatives have the potential to be anti-cancer molecules. In vitro, in vivo and limited clinical studies showed that GLA has selective tumoricidal action with little or no side effects. The mechanism of its action appears to be by inducing apoptosis of tumor cells by augmenting free radical generation only in the tumor cells but not normal cells. Intra-arterial injection of a lithium salt derivative of GLA demonstrated its ability to selectively occlude tumor-feeding vessels. Since GLA is an endogenous naturally occurring molecule and has no significant side effects, it calls for more studies to exploit its potential as a novel anti-cancer drug.
Export Options
About this article
Cite this article as:
Das N. Undurti, Tumoricidal and Anti-Angiogenic Actions of Gamma-Linolenic Acid and Its Derivatives, Current Pharmaceutical Biotechnology 2006; 7 (6) . https://dx.doi.org/10.2174/138920106779116892
DOI https://dx.doi.org/10.2174/138920106779116892 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cholangiocarcinoma Therapeutics: An Update
Current Cancer Drug Targets Non-histone Methylation of SET7/9 and its Biological Functions
Recent Patents on Anti-Cancer Drug Discovery Hypomethylation and Activation of Syncytin-1 Gene in Endometriotic Tissue
Current Pharmaceutical Design microRNAs: Innovative Targets for Cerebral Ischemia and Stroke
Current Drug Targets DNMT Inhibitors in Cancer, Current Treatments and Future Promising Approach: Inhibition of Specific DNMT-Including Complexes
Epigenetic Diagnosis & Therapy (Discontinued) The CXCL12/CXCR4 Axis as a Therapeutic Target in Cancer and HIV-1 Infection
Current Medicinal Chemistry Tumour-Derived Glutamate: Linking Aberrant Cancer Cell Metabolism to Peripheral Sensory Pain Pathways
Current Neuropharmacology Treatment of CNS Malignancies with a Recombinant Oncolytic Poliovirus
Drug Design Reviews - Online (Discontinued) Gene Therapy for Brain Cancer: Combination Therapies Provide Enhanced Efficacy and Safety
Current Gene Therapy The Problem of Amino Acid Complementarity and Antisense Peptides
Current Protein & Peptide Science Antitumor Properties of Natural Compounds and Related Molecules
Recent Patents on Anti-Cancer Drug Discovery Development of Decision Tree Models for Substrates, Inhibitors, and Inducers of P-Glycoprotein
Current Drug Metabolism Lenalidomide in an in vitro Dendritic Cell Model for Malignant Gliomas
Anti-Cancer Agents in Medicinal Chemistry Wnt/beta-catenin and PI3K/Akt/mTOR Signaling Pathways in Glioblastoma: Two Main Targets for Drug Design: A Review
Current Pharmaceutical Design Immunotherapy of Malignant Gliomas Using Autologous and Allogeneic Tissue Cells
Anti-Cancer Agents in Medicinal Chemistry Sphingolipid Modulation: A Strategy for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry 9th International Meeting on Metabotropic Gglutamate Receptors (Taormina, Sicily, October 1-6, 2017).
Current Neuropharmacology In Vitro Intestinal Co-Culture Cell Model to Evaluate Intestinal Absorption of Edelfosine Lipid Nanoparticles
Current Topics in Medicinal Chemistry The Function and Regulation of BMP6 in Various Kinds of Stem Cells
Current Pharmaceutical Design Host Pharmacogenetics in the Treatment of HIV and Cancer
Current Drug Safety